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Ideally, collection of clinical data should be an integral part of
healthcare systems.Without systematic collection of individual
patient data and outcome it is impossible for individual doctors,
healthcare providers, or regulatory agencies to understand how,
when, and to whom healthcare is provided and the actual
outcome of specific procedures or devices. Furthermore,
complications of new devices or strategies, particularly those
that are unexpected or infrequent, may be impossible to identify
without systematic data collection in a registry.
As well as complications, a registry can identify and limit use
of new treatments outside that for which they were clinically
approved. For example, drug eluting stents were primarily used
for off label indications during 2005-6. New treatments may
also be underused because of financial barriers, insufficient
training, or lack of confidence among doctors. A continuous
registry may be able to identify such underuse and provide
arguments for additional resources or more training .
Registries should always aim for consecutive enrolment of
patients from a large geographical area, preferably nationwide.
Selective enrolment will confound the data and limit the ability
to describe the patient population of interest. Included data
variables need to be adapted to a common standard such as the
European Society of Cardiology’s cardiology audit and
registration data standards for interventional cardiology.
Registries should ideally be driven by the profession with close
contact with local physicians to ensure high quality of the data
input. This model has proved successful in the SWEDEHEART
registry of coronary and valvular interventions1 in Sweden and
MINAP, a registry of patients admitted to hospital with acute
coronary syndromes in England and Wales.2 Sweden’s registry
captures 100% of patients having catheterisation or percutaneous
coronary intervention, and data are accurate. Participation at
the local level should be stimulated by providing online
automated reports and options to assess performance against
guidelines or national standards. National data should be
automatically exported to a European registry. The data should
be available to a steering committee that decides who can get
access and under what circumstances.
Opportunities and limitations of registries
Clinical evidence should primarily be based on results of
appropriately designed randomised clinical trials. However,
their results are often limited by including selected populations,
and they are expensive and cumbersome to perform.
Furthermore, for many subsets of patients randomised trials will
never be (and can never be) performed. In this case observational
studies are often the only option.
Retrospective analyses of prospectively collected registry data
are inexpensive—the only costs relate to the analyses—and
reflect the true clinical situation. They are ideal for descriptive
studies and for outcome analyses but have limited value for
comparisons between therapeutic options. Nevertheless,
registries can be used as a platform for randomisation and thus
allow large scale studies to be done at low cost. For example,
the Swedish Coronary Angiography and Angioplasty Registry
(SCAAR) is being used to prospectively evaluate mortality in
patients given manual thrombus aspiration before primary
percutaneous coronary intervention compared with that in
patients given no aspiration.3
Postmarketing surveillance
Registries also have great potential for postmarketing
surveillance. In Europe devices receive approval for use and
CE marking from notified bodies and national competent
authorities based on limited clinical documentation. Reports of
problems with devices should be submitted to notified bodies,
but it has been estimated that voluntary reporting may capture
less than 10% of relevant events. We recommend that approval
for commercial use of devices without adequate clinical data
should be conditional on rigorous postmarketing surveillance
studies to prove safety and efficacy in broad populations.4 It is
the manufacturer’s responsibility to monitor the performance
of their devices, for as long as they are in use, and
to ensure these devices continue to be safe and suitable for
clinical use. It is also important that the European database on
medical devices (EUDAMED) should be in the public domain.
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Although all countries are required to submit safety
data—including CE certification, clinical data, and device
failures—to the database from this month, the information will
be available only to marketing surveillance authorities.
Large scale postmarketing studies are costly, require specially
designed web based clinical report forms, and are often funded
and driven by industry. Instead postmarketing studies should
be done within existing large registries developed by
professional organisations. This will ensure broad unselected
populations and avoid competition between randomised trials
and registries. It would also stimulate input from academia and
support the development of large continuous quality registries.
When licensing authorities request postmarketing surveillance
studies, the manufacturers should have to provide financial
support to the registry.
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